Confirmation of safety of new gastrointestinal peptide Ghrelin in patients with chronic kidney disease
Phase 2
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000021580
- Lead Sponsor
- Division of Nephrology, Endocrinology and Metabolism School of Medicine Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
patients with severe liver dysfunction patients with malignant neoplasm patients with severe infection patients with psycological problems patients who have allergy for wheat,milk and egg patients who plans for pregnancy who are judged to be inappropriate for the study by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time course of ghrelin blood concentration
- Secondary Outcome Measures
Name Time Method onset rate of any serious adverse events